2025-05-30 - Analysis Report
Okay, here's the report summarizing the provided information on Eli Lilly and Co. (LLY).

**Report on Eli Lilly and Co. (LLY)**

Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** LLY
*   **Cumulative Return (LLY):** 242.27%
*   **Cumulative Return (VOO):** 82.09%
*   **Absolute Spread:** 160.18% (LLY outperformed VOO)
*   **Spread Range:** Max: 313.1, Min: -27.6
*   **Relative Spread:** 55.1% (LLY's current outperformance positions it at the 55.1th percentile of its historical range relative to VOO).

**Alpha and Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 10.0%  | 56.3% | -19.0%  | 0.1    | 67.5   |
| 2016-2018  | 38.0%  | 58.6% | 20.0%   | -0.1   | 94.9   |
| 2017-2019  | 49.0%  | 58.6% | 19.0%   | 0.3    | 110.2  |
| 2018-2020  | 51.0%  | 58.6% | 25.0%   | 0.1    | 144.4  |
| 2019-2021  | 105.0% | 60.6% | 50.0%   | 0.3    | 239.8  |
| 2020-2022  | 100.0% | 65.0% | 94.0%   | 0.3    | 321.9  |
| 2021-2023  | 139.0% | 65.0% | 122.0%  | 0.3    | 518.0  |
| 2022-2024  | 156.0% | 72.2% | 139.0%  | 0.3    | 690.4  |
| 2023-2025  | 92.0%  | 76.8% | 62.0%   | 0.2    | 648.7  |

*   **Analysis:** The table shows strong growth and outperformance (positive Alpha) by LLY over various periods. Beta values are generally low, indicating the stock is less sensitive to market movements. CAGR (Compound Annual Growth Rate) has been very strong in recent years. However, MDD(Maximum Drawdown) is gradually getting bigger.

**2. Recent Price Action:**

*   **Last Price:** $722.57
*   **Previous Close:** $719.39
*   **Change:** 0.44% (Slight increase)
*   **5-Day Moving Average:** $719.22
*   **20-Day Moving Average:** $749.54
*   **60-Day Moving Average:** $794.67

*   **Analysis:** The stock is currently trading above its 5-day moving average, but below its 20-day and 60-day moving averages.  This suggests a short-term uptrend, but a potential longer-term downtrend or consolidation. The slight increase from the previous close doesn't indicate a major volatility event.

**3. Market Risk Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 42.62 (Neutral, not overbought or oversold)
*   **PPO:** -0.2869 (Slightly negative, suggesting slight bearish momentum)
*   **Hybrid Signal:** cash_69%_Sell 69.8% of holdings (397 shares)
*   **Recent Relative Spread Change (20-day):** -0.6 (Indicates short-term underperformance relative to the benchmark)
*   **Expected Return:** 126.5% (Long-term projection, exceeding S&P 500)

*   **Analysis:**  The MRI indicates low market risk. However, the hybrid signal suggests a significant sell recommendation, potentially driven by concerns about valuation or short-term performance. The negative change in relative spread supports this cautious outlook.  The high expected return suggests significant long-term growth potential, but the current signals suggest some caution.

**4. Recent News & Significant Events:**

*   **Summary:** Recent news indicates significant business developments, regulatory changes, and market volatility influencing LLY's stock. Analysts are discussing the company's performance in relation to industry trends and global economic factors. Investors are advised to monitor news and company announcements.

*   **Impact:** These news items suggest a dynamic environment for LLY, requiring close monitoring of developments that could impact stock performance.

**5. Recent Earnings Analysis:**

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-05-01   | 3.07 | 12.73 B$    |
| 2024-10-30   | 1.08 | 11.44 B$    |
| 2024-08-08   | 3.29 | 11.30 B$    |
| 2024-04-30   | 2.49 | 8.77 B$     |
| 2025-05-01 | 2.49 | 8.77 B$ |

*   **Analysis:** Earnings per share (EPS) and revenue have shown variability. The most recent EPS (3.07) is strong, and revenue (12.73 B$) is also solid. This indicates potential for continued growth, but the fluctuations should be considered.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |
| 2024-03-31   | $8.77B     | 80.91%        |

Capital and Profitability:

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-03-31   | $15.76B   | 17.50%  |
| 2024-12-31   | $14.19B   | 31.07%  |
| 2024-09-30   | $14.24B   | 6.81%   |
| 2024-06-30   | $13.56B   | 21.88%  |
| 2024-03-31   | $12.81B   | 17.51%  |

*   **Analysis:** Revenue and profit margins are consistently high, indicating strong operational efficiency. Equity is increasing, but ROE (Return on Equity) fluctuates. This shows effective capital management and strong profitability.

**7. 종합 Analysis:**

LLY has demonstrated significant outperformance compared to the S&P 500, driven by strong growth in recent years, as evidenced by its CAGR and Alpha values. Recent earnings and financial data confirm solid revenue, high profit margins, and effective capital management.

However, the current market signals are mixed. While the MRI indicates low market risk, the hybrid signal suggests a sell recommendation, possibly due to valuation concerns. The stock is trading below its 20-day and 60-day moving averages, indicating potential short-term weakness, and the recent decline in relative spread further supports this cautious outlook.

Recent news highlights dynamic developments influencing the stock, requiring investors to stay informed.

Overall, LLY appears to be a strong company with significant long-term growth potential. However, current market signals warrant caution and suggest potential short-term downside.
